Grace Therapeutics, Inc.
GRCECIK 0001444192 · Pharmaceutical Preparations · Nasdaq
- Acasti Pharma Inc. (until 2024-10-25)
Revenue (TTM)
$100M
FY Jun 2026
Net Income (TTM)
−$10.77M
+18.6% YoY
FY Jun 2026
EPS Diluted (TTM)
−$0.77
+40.5% YoY
FY Jun 2026
Gross Margin
100.0%
FY Jun 2026
Operating Margin
-11.8%
FY Jun 2026
Net Margin
-10.8%
FY Jun 2026
Free Cash Flow (TTM)
−$17.38M
FY Jun 2026
Cash
$16.98M
FY Jun 2026
Total Debt
—
FY Jun 2026
Shares Outstanding
16.27M sh
FY Jun 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.
Balance Sheet
Cash vs Debt
Latest news
All news →-
High Negative
Grace Therapeutics Reports $7.8M Net Loss; FDA Meeting Scheduled on GTx-104
The biopharma firm faces FDA manufacturing questions on its aneurysmal hemorrhage candidate but plans to resubmit after clarification meeting.